SUPPORTING INFECTIOUS DISEASE RESEARCH

# Klebsiella pneumoniae, Strain MRSN 7076

#### Catalog No. NR-55513

This reagent is the tangible property of the U.S. Government.

#### **Product Description:**

*Klebsiella pneumoniae (K. pneumoniae)*, strain MRSN 7076 was isolated in 2003 from a human wound sample in North America as part of a global surveillance program. NR-55513 was deposited as an extensively drug-resistant strain, sensitive to amikacin, ceftazidime/avibactam, ciprofloxacin, ertapenem, imipenem, levofloxacin and meropenem, intermediately resistant to piperacillin/tazobactam and resistant to ampicillin/sulbactam, aztreonam, cefepime, ceftazidime, ceftolozane/tazobactam, ceftriaxone, gentamicin, tetracycline, trimethoprim/sulfamethoxazole, tigecycline and tobramycin. NR-55513 was produced by inoculation of the deposited material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

## Lot: 70049657

# Manufacturing Date: 19JAN2022

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: <u>Contact@BEIResources.org</u>. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology	Report results	Circular, convex, entire, smooth and cream (Figure 1)
Motility (wet mount)	Report results	Non-motile
VITEK <sup>®</sup> MS (MALDI-TOF)	K. pneumoniae	K. pneumoniae (98%)
Antibiotic Susceptibility Profile <sup>1,2</sup>		
Amikacin	Sensitive	Sensitive (≤ 2 µg/mL)
Ampicillin/sulbactam	Resistant	Resistant (≥ 32 µg/mL)
Aztreonam	Resistant	Resistant (≥ 64 µg/mL)
Cefepime	Resistant	Intermediate (8 µg/mL) <sup>3</sup>
Ceftazidime	Resistant	Resistant (16 µg/mL)
Ceftazidime/avibactam	Sensitive	Sensitive (1.5 µg/mL)
Ceftolozane/tazobactam	Resistant	Sensitive (1.5 µg/mL) <sup>4</sup>
Ceftriaxone	Resistant	Resistant (≥ 64 µg/mL)
Ciprofloxacin	Sensitive	Sensitive (0.5 µg/mL)
Ertapenem	Sensitive	Sensitive (≤ 0.5 µg/mL)
Gentamicin	Resistant	Resistant (≥ 16 µg/mL)
Imipenem	Sensitive	Sensitive (0.19 µg/mL)
Levofloxacin	Sensitive	Sensitive (1 µg/mL)
Meropenem	Sensitive	Sensitive (≤ 0.25 µg/mL)
Piperacillin/tazobactam	Intermediate	Intermediate (32 to 48 µg/mL)
Tetracycline	Resistant	Resistant (≥ 16 µg/mL)
Tigecycline	Resistant	Resistant (≥ 8 µg/mL) <sup>5</sup>
Tobramycin	Resistant	Resistant (≥ 16 µg/mL)
Trimethoprim/sulfamethoxazole	Resistant	Resistant (≥ 320 µg/mL)
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene (~ 1470 base pairs)	≥ 99% sequence identity to <i>K. pneumoniae</i> , strain MRSN 7076 (GenBank: JAGYET010000100.1)	99.7% sequence identity to <i>K. pneumoniae</i> , strain MRSN 7076 (GenBank: JAGYET010000100.1) <sup>6</sup>

E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898 biei resources

# **Certificate of Analysis for NR-55513**

#### SUPPORTING INFECTIOUS DISEASE RESEARCH

TEST	SPECIFICATIONS	RESULTS
Purity 7 days at 37°C in an aerobic atmosphere with 5% CO <sub>2</sub> on Tryptic Soy agar with 5% defibrinated sheep blood		Growth consistent with expected colony morphology
Viability	Growth	Growth

<sup>1</sup>Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

<sup>2</sup>Antibiotic susceptibility was tested using a combination of bioMérieux VITEK<sup>®</sup>2 GN74 and ETEST<sup>®</sup>.

<sup>3</sup>The susceptibility result for this antibiotic is within one doubling dilution of specification, which is considered an equivalent result.

<sup>4</sup>K. pneumoniae, strain MRSN 7076 was deposited as resistant to ceftolozane/tazobactam, but showed a MIC of 1.5 μg per mL (interpreted as sensitive) for this antibiotic during QC testing. Testing was performed in duplicate.

<sup>5</sup>MIC Interpretation Guideline: EUCAST Version 8.0 (2018)

<sup>6</sup>Also consistent with other *Klebsiella* species

### Figure 1: Colony Morphology



# /Sonia Bjorum Brower/ Sonia Bjorum Brower

Lead Technical Writer or designee, ATCC Federal Solutions

ATCC<sup>®</sup>, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC<sup>®</sup>'s knowledge.

ATCC<sup>®</sup> is a trademark of the American Type Culture Collection. You are authorized to use this product for research use only. It is not intended for human use.



01 JUL 2022